The startup has developed a drug formulation platform that utilizes a novel class of non-aqueous, non-lipid liquids to enhance the oral bioavailability of poorly water-soluble small molecules. This technology enables pharmaceutical companies to improve the absorption of medications, addressing the challenge of low solubility in drug delivery.
Funding
$340K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many small molecule and peptide drugs exhibit poor oral bioavailability due to limited solubility and permeability, hindering their therapeutic effectiveness. Traditional formulation strategies often fail to adequately address these challenges, resulting in suboptimal drug absorption and reduced clinical efficacy.
Solution
SeraNovo offers a drug formulation platform leveraging non-aqueous, non-lipid liquids to enhance the oral bioavailability of poorly water-soluble compounds. Their NanoGlass™ technology encompasses several platforms, including HyGlass™, GlassE™, PeptiDES™, and LiGlass™, each tailored to specific drug characteristics. These platforms create stable formulations that improve drug solubility, protect against enzymatic degradation, and facilitate absorption. SeraNovo's approach enables pharmaceutical companies to develop more effective oral medications with improved patient outcomes, offering rapid formulation development in 4-8 weeks using minimal API and one-step manufacturing processes.
Target Audience
The primary target audience includes pharmaceutical companies seeking to improve the oral bioavailability of their small molecule and peptide drug candidates, as well as those looking to rescue failed drug candidates with poor absorption characteristics.
Features
- **HyGlass™:** Enhances solubility and bioavailability for APIs with high melting points and weakly basic properties, achieving up to 25% drug loading.
- **GlassE™:** A dehydrated solid powder formulation that rehydrates upon ingestion for rapid dissolution and enhanced absorption, achieving up to 40% drug loading.
- **PeptiDES™:** Employs a eutectic solvent-based formulation to protect peptides from enzymatic breakdown and enhance intestinal absorption.
- **LiGlass™:** Combines a lipid-based formulation with a unique solvent system to improve bioavailability for drugs with high Log P values and melting points below 200°C, achieving up to 30% drug loading.
- Prototype formulations developed in 4-8 weeks.
- Utilizes FDA-approved inactive ingredients.
- Demonstrated 1.5-3-fold higher bioavailability enhancement compared to competing technologies.